Injunction Issued Against Life Technologies
According to court documents, Life Technologies has filed an appeal with the US Court of Appeals for the Federal Circuit. In July, in its answer to the initial filing, Life Technologies alleged that the Patent is unenforceable due to inequitable conduct by the plaintiff that misled the Patent and Trademark Office. Life Technologies also requested that the Patent be declared invalid and unenforceable and that it be rewarded costs, disbursements and attorneys’ fees.
Chicago, IL 9/10/10—Celsis In Vitro (Celsis IVT) announced that the US District Court for the Northern District of Illinois has entered a preliminary injunction against CellzDirect, part of Life Technologies’ Invitrogen business, due to their infringement of US Patent No. 7,604,929 (see IBO 6/30/10). The Patent relates to methods for producing multi-cryopreserved hepatocytes and methods for using them to investigate in vitro drug metabolism. “Companies that produce infringing products, piggybacking on years of research and development by other scientists, have no costs to recoup. It’s all too easy for them to offer products for sale at significant discounts compared to patented products that must recoup major R&D investments,” stated Celsis CEO Jay LeCoque. Cell IVT alleges the defendants are selling products from infringing methods, providing infringing services and inducing infringement of the patents. The company also seeks monetary damages and a permanent injunction. Life Technologies issued no statement.
